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Introduction
With a focus on early diagnosis and improved treatment
strategies, investigative studies and clinical trials over the past
two decades have improved the recurrence-free and overall
survival rates in breast cancer patients. However, women and
their physicians have increasingly recognized the substantial
cost and emotional burden resulting from breast cancer
diagnosis and treatment. Prevention of the disease avoids
these problems but requires an ability to predict risk. Selection
of women at higher risk enhances the benefit/risk ratio of
preventative agents [1]. Several valid methods are currently
available for risk assessment, but their ability to identify women
at moderate risk is limited [2]. Several factors, not included in
the currently available models, could potentially enhance the
predictive power of risk prediction methods. These factors
include measurement of plasma androgens and oestrogens,
as well as mammographic density, bone density and body
mass index (BMI). A history of weight gain, age of menopause,
fracture, alcohol use, magnitude of exercise and duration of
breast feeding could also contribute.
Plasma hormone levels and breast cancer risk
Data from a large collaborative European study reported by
Kaaks and coworkers [3] provide strong prospective evidence
for the independent roles played by androgens and oestrogens
in predicting breast cancer risk. In a similar study, Key and
colleagues [4] pooled data from nine studies of similar type and
drew comparable conclusions. A summary of the details of
these studies is beyond the scope of this short communication
but can be found in the report by Santen and coworkers [1],
with specific details provided elsewhere [3,4].  The
methodology involved the collection of a single blood sample
from each postmenopausal woman and subsequent follow-up
over a period of 2 to 12 years. Women developing breast
cancer and those who did not were grouped according to
hormone levels into those in the first, second, third, fourth and
fifth quintiles. The relative risk for breast cancer in quintiles two
to four were compared with those in the first quintile.
Based upon these collaborative studies, the relative risks
(RRs; and 95% confidence intervals [CIs]) for developing
breast cancer in women in the top quintile of each hormone
level compared with the bottom quintile are summarized in
rank order in Table 1 [3,4].
Total plasma oestradiol (E2) correlated (correlation coefficient
or R value) substantially with the other hormones measured.
Correlation coefficients were as follows: 0.96 for free E2,
0.87 for non-sex hormone binding globulin E2, 0.59 for
oestrone, and 0.60 for oestrone sulphate (E1S). Correlations
of E2 with androgens were significant but weaker: 0.37 for
testosterone, 0.35 for androstenedione, 0.29 for dehydro-
epiandrosterone (DHEA) sulphate, and 0.2 for DHEA. Levels
of androgens and oestrogens appeared to provide indepen-
dent information, according to the available statistical analy-
ses. For example, when E2 was not adjusted for androgens,
the RR associated with a doubling of hormone concentration
was 1.31 (95% CI 1.17 to 1.48), and 1.18 (95% CI 1.04 to
1.34) when E2 was adjusted for testosterone. When
testosterone was unadjusted, the RR associated with a
doubling of hormone concentration was 1.42 (95% CI 1.25
to 1.61) and 1.32 (95% CI 1.15 to 1.51) when adjusted for
E2. When corrected for the level of BMI, the predictive nature
of the oestrogen levels was considerably reduced because
BMI correlates well with free plasma E2 level [5]. The
measurement of these hormones was then examined in
women who were otherwise at high risk for breast cancer
based on other epidemiological factors. Even in the highest
category of risk, measurements of androgens and oestrogens
provided a statistically significant assessment of risk [6].
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It is not surprising that the oestrogens correlated one with
another. Prior studies in cell culture models demonstrated
that titrated E1S is converted into E2 and that the oestrogen
found in the nucleus under these conditions is E2. E1S can
stimulate growth of MCF-7 breast cancer cells in proportion
to its conversion to E2 and appearance in the nucleus as E2
[7]. Why would androgens correlate with breast cancer risk
independently of oestrogens? One hypothesis suggests that
plasma oestrogens reflect the extraglandular production of
oestrogens in fat tissue and androgens provide the substrate
for aromatase in the breast itself. Both are regulated
differently and thus could provide independent information.
Careful analysis of the prospective studies of hormones and
breast cancer risk uncovers problems with currently available
E2 radioimmunoassays (RIAs). There was a nearly fivefold
difference in mean levels of E2 among the nine different
studies identified by Key and coworkers [4], presumably as a
result of lack of sensitivity and precision of the RIAs used to
measure these steroids in postmenopausal women. For this
reason, we have reported data comparing E2 levels by gas
chromatography/tandem mass spectrometry (GC/MS/MS)
and RIA in three groups of postmenopausal women [8].
Although the overall correlation of oestrogen levels is
excellent (r = 0.83, P < 0.001), the correlation breaks down
when correlations are made in the lowest tertile of values
(r = 0.29, not significant). Accumulating data suggest that the
RIAs are measuring cross-reacting material, which elevates
the oestrogen levels above those detected by RIA [9]. For
example, the yeast recombinant DNA and HeLa cell
bioassays, as well as the GC/MS/MS methods, all measure
substantially lower oestrogen levels than RIA. We conclude
that the correlative studies must be repeated using more valid
GC/MS/MS assays. With such assays, it should be possible
to identify a group of women at much lower risk for breast
cancer, whose E2 levels could be accurately measured using
the more sophisticated methodology [2].
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Table 1
Relative risks for breast cancer associated with hormone
levels: top versus bottom quintile
Hormone RR (95% CI)
Free E2 2.58 (1.76 to 3.78)
Non-SHBG-E2 2.39 (1.62 to 3.54)
Testosterone 2.22 (1.59 to 3.10)
Estrone 2.19 (1.48 to 3.22) 
Androstenedione 2.15 (1.44 to 3.21)
DHEA 2.04 (1.21 to 3.45)
Total estradiol  2.00 (1.47 to 2.71)
Estrone sulfate  2.00 (1.26 to 3.16)
DHEAS 1.75 (1.26 to 2.43)
SHBG 0.66 (0.43 to 1.00)
Data from Kaaks [3] and Key [4], and their coworkers. DHEA,
dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate;
E2, oestradiol; SHBG, sex hormone binding globulin.